




追跡試験 24±10 月

FIG. 2







生存率の変化





FIG. 5







FIG. 6







FIG. 7







FIG. 8






FIG. 9

## Cox比例ハザードモデルによる肝癌再発危険の割合 (RR)

		RR	p	95% C.I.
	VK-II非投与	1		
全症例				
	VK-II投与	0.329	0.0013	0.167-0.648
	VK-II非投与	1		
HCV例			·	
	VK-II投与	0.210	0.0001	0.094-0.468

